Risk factors and outcomes for patients with vascular disease and serious bleeding events

被引:24
作者
Alberts, Mark J. [1 ]
Bhatt, Deepak L. [2 ,3 ,4 ]
Smith, Sidney C., Jr. [5 ]
Roether, Joachim [6 ]
Goto, Shinya [7 ,8 ]
Hirsch, Alan T. [9 ]
Steg, Ph Gabriel [10 ]
机构
[1] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA
[2] VA Boston Healthcare Syst, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA
[6] Asklepios Klin Altona, Dept Neurol, Hamburg, Germany
[7] Tokai Univ, Sch Med, Dept Med, Kanagawa 2591100, Japan
[8] Tokai Univ, Sch Med, Metab Dis Ctr, Kanagawa 2591100, Japan
[9] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA
[10] Univ Paris 07, INSERM, U698, AP HP, Paris, France
关键词
ACUTE CORONARY SYNDROMES; LOW-DOSE ASPIRIN; ANTITHROMBOTIC THERAPY; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; PLATELET INHIBITION; ATRIAL-FIBRILLATION; CLINICAL-OUTCOMES; BLOOD-TRANSFUSION; ADVERSE EVENTS;
D O I
10.1136/hrt.2010.221788
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective To determine the risk and outcomes of serious bleeding events in patients with atherosclerotic vascular disease or risk factors. Methods 68 375 outpatients with prior ischaemic vascular events or multiple atherosclerotic risk factors were followed in this prospective observational study; 64 977 had 1-year follow-up data. Main outcome measures were rates of serious bleeding events and 1-year outcomes for patients with and without serious bleeding events. Results The 1-year rate of serious haemorrhage was 0.92%, with a cerebral haemorrhage rate of 0.11%. Patients with symptomatic vascular disease had a haemorrhage rate of 1.0%, compared with 0.59% in those with risk factors only. Risk factors for serious bleeding included age, smoking, hypertension, diabetes, congestive heart failure, use of antithrombotics and polyvascular disease. Bleeding risk increased with the use of anticoagulants (OR 1.99, 95% CI 1.38 to 2.86, p<0.001) or antiplatelet agents combined with anticoagulants (OR 2.54, 95% CI 1.74 to 3.71, p<0.001). By logistic regression analysis, patients with a serious bleed (excluding cerebral haemorrhage) had a more than threefold increased risk (HR 3.25, 95% CI 2.58 to 4.10, p<0.0001) of a significant vascular outcome (myocardial infarction, stroke, vascular death) compared with patients without a serious bleed. Conclusions Serious bleeding complications were relatively rare, but significant considering the large population at risk. Predictors of increased bleeding were similar to the risk factors for ischaemic events. Patients who experienced a serious bleed had a significantly higher rate of major vascular events.
引用
收藏
页码:1507 / 1512
页数:6
相关论文
共 40 条
[1]
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry [J].
Alberts, Mark J. ;
Bhatt, Deepak L. ;
Mas, Jean-Louis ;
Ohman, E. Magnus ;
Hirsch, Alan T. ;
Roether, Joachim ;
Salette, Genevieve ;
Goto, Shinya ;
Smith, Sidney C., Jr. ;
Liau, Chiau-Suong ;
Wilson, Peter W. F. ;
Steg, Ph. Gabriel .
EUROPEAN HEART JOURNAL, 2009, 30 (19) :2318-2326
[2]
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients [J].
Andreotti, F ;
Testa, L ;
Biondi-Zoccai, GGL ;
Crea, F .
EUROPEAN HEART JOURNAL, 2006, 27 (05) :519-526
[3]
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease [J].
Berger, Peter B. ;
Bhatt, Deepak L. ;
Fuster, Valentin ;
Steg, P. Gabriel ;
Fox, Keith A. A. ;
Shao, Mingyuan ;
Brennan, Danielle M. ;
Hacke, Werner ;
Montalescot, Gilles ;
Steinhubl, Steven R. ;
Topol, Eric J. .
CIRCULATION, 2010, 121 (23) :2575-2583
[4]
Scotblood 2007: Tackling local and global issues in transfusion medicine - Donor recruitment, effective use of blood, stem cell plasticity, and vCJD [J].
Bessos, Hagop ;
Fraser, Robin ;
Seghatchian, Jerard .
TRANSFUSION AND APHERESIS SCIENCE, 2008, 38 (01) :77-83
[5]
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[6]
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis [J].
Bhatt, DL ;
Steg, PG ;
Ohman, EM ;
Hirsch, AT ;
Ikeda, Y ;
Mas, JL ;
Goto, S ;
Liau, CS ;
Richard, AJ ;
Röther, J ;
Wilson, PWF ;
Andersen-Dalheim, H ;
Anderson, P ;
Anell, B ;
Arber, S ;
Armstrong, K ;
Arnot, D ;
Baldam, A ;
Barratt, I ;
Barresi, S ;
Beder, J ;
Benson, M ;
Bergman, F ;
Best, J ;
Bhasim, R ;
Bovell, G ;
Bowman, N ;
Brkic, M ;
Bromberger, D ;
Brown, D ;
Brown, J ;
Brownstein, M ;
Bruce, A ;
Buonopane, J ;
Burns, S ;
Butler, A ;
Byrne, D ;
Carson, J ;
Cassimatis, P ;
Chaffey, G ;
Chambers, D ;
Chan, WJ ;
Chan, B ;
Cheatham, J ;
Chen, R ;
Cheong, B ;
Cheung, C ;
Chin, J ;
Chiu, A ;
Choo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02) :180-189
[7]
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease [J].
Biondi-Zoccai, Giuseppe G. L. ;
Lotrionte, Marzia ;
Agostoni, Pierfrancesco ;
Abbate, Antonio ;
Fusaro, Massimiliano ;
Burzotta, Francesco ;
Testa, Luca ;
Sheiban, Imad ;
Sangiorgi, Giuseppe .
EUROPEAN HEART JOURNAL, 2006, 27 (22) :2667-2674
[8]
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[9]
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease - A meta-analysis of randomized trials [J].
Dentali, Francesco ;
Douketis, James D. ;
Lim, Wendy ;
Crowther, Mark .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (02) :117-124
[10]
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis [J].
Ducrocq, Gregory ;
Wallace, Joshua S. ;
Baron, Gabriel ;
Ravaud, Philippe ;
Alberts, Mark J. ;
Wilson, Peter W. F. ;
Ohman, Erik Magnus ;
Brennan, Danielle M. ;
D'Agostino, Ralph B. ;
Bhatt, Deepak L. ;
Steg, Philippe Gabriel .
EUROPEAN HEART JOURNAL, 2010, 31 (10) :1257-1265